|
GS204629: GO:1901564 organonitrogen compound metabolic process
|
|
GS185985: GO:0016818 hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides
|
|
GS166812: MP:0002209 decreased germ cell number
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS190997: GO:0044281 small molecule metabolic process
|
|
GS167063: MP:0001929 abnormal gametogenesis
|
|
GS136535: promotion susceptibility QTL 2 (Psl2, Published QTL Chr 2)
|
|
GS191019: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS165218: MP:0001240 abnormal epidermis stratum corneum morphology
|
|
GS191088: GO:0009199 ribonucleoside triphosphate metabolic process
|
|
GS204630: GO:1901565 organonitrogen compound catabolic process
|
|
GS135237: activity response to ethanol 4 (Actre4, Published QTL Chr 2)
|
|
GS192017: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS202471: GO:0035870 dITP diphosphatase activity
|
|
GS196343: GO:0036094 small molecule binding
|
|
GS136403: organ weight QTL 3 (Orgwq3, Published QTL Chr 2)
|
|
GS165975: MP:0002740 heart hypoplasia
|
|
GS180276: GO:0006195 purine nucleotide catabolic process
|
|
GS191106: GO:0044464 cell part
|
|
GS210137: GO:0016462 pyrophosphatase activity
|
|
GS136018: heart failure modifier 5 (Hrtfm5, Published QTL Chr 2)
|
|
GS177404: GO:0005737 cytoplasm
|
|
GS177570: GO:0016043 cellular component organization
|
|
GS201251: GO:0044424 intracellular part
|
|
GS135670: circadian period of locomotor activity 7 (Cplaq7, Published QTL Chr 2)
|
|
GS178359: GO:0071840 cellular component organization or biogenesis
|
|
GS165874: MP:0002133 abnormal respiratory system physiology
|
|
GS181533: GO:0046872 metal ion binding
|
|
GS135502: bladder tumor susceptibility 1 (Bts1, Published QTL Chr 2)
|
|
GS136639: salmonella enteritidis susceptibility 7 (Ses7, Published QTL Chr 2)
|
|
GS162825: MP:0001636 irregular heartbeat
|
|
GS196894: GO:0009207 purine ribonucleoside triphosphate catabolic process
|
|
GS136735: segregation of mitochondrial DNA QTL 2 (Smdq2, Published QTL Chr 2)
|
|
GS135219: aberrant activation of B cell proliferation (Aabpr, Published QTL Chr 2)
|
|
GS170243: MP:0011085 complete postnatal lethality
|
|
GS180291: GO:0006193 ITP catabolic process
|
|
GS192094: GO:0047429 nucleoside-triphosphate diphosphatase activity
|
|
GS136417: orthodenticle homolog 2 (Drosophila) modifier 2 (Otx2m2, Published QTL Chr 2)
|
|
GS178357: GO:0071842 cellular component organization at cellular level
|
|
GS177311: GO:1901361 organic cyclic compound catabolic process
|
|
GS166660: MP:0001731 abnormal postnatal growth
|
|
GS136115: body length 2 (Lgth2, Published QTL Chr 2)
|
|
GS163226: MP:0003312 abnormal locomotor coordination
|
|
GS34890: Whole Brain Gene expression correlates of Open Field - Total time in corners in Females BXD
|
|
GS209108: GO:0000166 nucleotide binding
|
|
GS165595: MP:0010545 abnormal heart layer morphology
|
|
GS192074: GO:1901575 organic substance catabolic process
|
|
GS180118: GO:0009207 purine ribonucleoside triphosphate catabolic process
|
|
GS193888: GO:0051276 chromosome organization
|
|
GS163824: MP:0001259 abnormal body weight
|
|
GS203608: GO:0034655 nucleobase-containing compound catabolic process
|
|
GS181721: GO:0006163 purine nucleotide metabolic process
|
|
GS166591: MP:0004087 abnormal muscle fiber morphology
|
|
GS170363: MP:0000240 extramedullary hematopoiesis
|
|
GS177565: GO:0009166 nucleotide catabolic process
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS123167: cobaltous chloride interacting genes (MeSH:C018021) in CTD
|
|
GS206726: GO:0009261 ribonucleotide catabolic process
|
|
GS129170: prion disease incubation time 2 (Prdt2 Published QTL Chr 2)
|
|
GS208978: GO:0043169 cation binding
|
|
GS136872: T cell ratio modifier QTL 2 (Trmq2, Published QTL Chr 2)
|
|
GS165441: MP:0000382 underdeveloped hair follicles
|
|
GS165261: MP:0001393 ataxia
|
|
GS197071: GO:0006193 ITP catabolic process
|
|
GS192299: GO:0006793 phosphorus metabolic process
|
|
GS168826: MP:0005294 abnormal heart ventricle morphology
|
|
GS209928: GO:0006996 organelle organization
|
|
GS36378: Cerebellum Gene expression correlates of Open Field - Total rears 10-15 minutes in Females & Males BXD
|
|
GS178401: GO:0019637 organophosphate metabolic process
|
|
GS169828: MP:0005386 behavior/neurological phenotype
|
|
GS182835: GO:0005622 intracellular
|
|
GS167081: MP:0004090 abnormal sarcomere morphology
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS207903: GO:0044281 small molecule metabolic process
|
|
GS207995: GO:0009199 ribonucleoside triphosphate metabolic process
|
|
GS194133: GO:0005737 cytoplasm
|
|
GS135918: graft-versus host disease 3 (Gvhd3, Published QTL Chr 2)
|
|
GS186790: GO:0006725 cellular aromatic compound metabolic process
|
|
GS207389: GO:0009150 purine ribonucleotide metabolic process
|
|
GS194111: GO:0097159 organic cyclic compound binding
|
|
GS189860: GO:0043167 ion binding
|
|
GS167656: MP:0001943 abnormal respiration
|
|
GS191129: GO:0016787 hydrolase activity
|
|
GS163936: MP:0004091 abnormal Z lines
|
|
GS194307: GO:0016043 cellular component organization
|
|
GS206742: GO:0043167 ion binding
|
|
GS165386: MP:0001262 decreased body weight
|
|
GS202828: GO:0016817 hydrolase activity, acting on acid anhydrides
|
|
GS83987: cocaine related behavior 3 (Cocrb3, Published QTL, Chr 2)
|
|
GS36403: Cerebellum Gene expression correlates of Open Field - Total rears 15-20 minutes in Males BXD
|
|
GS163052: MP:0000266 abnormal heart morphology
|
|
GS136011: heart rate quantitative locus 1 (Hrq1, Published QTL Chr 2)
|
|
GS34252: Hippocampus Gene expression correlates of Activity in altered context during presentation of cue in Males BXD
|
|
GS209010: GO:1901575 organic substance catabolic process
|
|
GS169391: MP:0002066 abnormal motor capabilities/coordination/movement
|
|
GS128575: Ethanol induced LORR Chr# 2
|
|
GS194302: GO:0009166 nucleotide catabolic process
|
|
GS186238: GO:0009144 purine nucleoside triphosphate metabolic process
|
|
GS136600: serum alkaline phosphatase activity 1 (Salpa1, Published QTL Chr 2)
|
|
GS181473: GO:0005488 binding
|
|
GS192512: GO:0003824 catalytic activity
|
|
GS167928: MP:0010630 abnormal cardiac muscle tissue morphology
|
|
GS189896: GO:0009117 nucleotide metabolic process
|
|
GS169389: MP:0002060 abnormal skin morphology
|
|
GS136364: obesity QTL 10 (Obq10, Published QTL Chr 2)
|
|
GS164264: MP:0002082 postnatal lethality
|
|
GS181666: GO:0019439 aromatic compound catabolic process
|
|
GS163601: MP:0002089 abnormal postnatal growth/weight/body size
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS136160: leishmaniasis resistance 14 (Lmr14, Published QTL Chr 2)
|
|
GS135837: total fat pad mass QTL 1 (Fatmq1, Published QTL Chr 2)
|
|
GS165527: MP:0005378 growth/size phenotype
|
|
GS188962: GO:1901292 nucleoside phosphate catabolic process
|
|
GS198323: GO:0046872 metal ion binding
|
|
GS127938: Striatum - Allen Mouse Brain Atlas
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS184447: GO:0044424 intracellular part
|
|
GS129169: plasma plant sterol 2b (Plast2b Published QTL Chr 2)
|
|
GS207862: GO:0009056 catabolic process
|
|
GS198455: GO:0019439 aromatic compound catabolic process
|
|
GS193489: GO:0072521 purine-containing compound metabolic process
|
|
GS210435: GO:0072521 purine-containing compound metabolic process
|
|
GS178360: GO:0071841 cellular component organization or biogenesis at cellular level
|
|
GS210437: GO:0072523 purine-containing compound catabolic process
|
|
GS198012: GO:0046434 organophosphate catabolic process
|
|
GS36388: Cerebellum Gene expression correlates of Open Field - Total rears 10-15 minutes in Males BXD
|
|
GS170674: MP:0000278 abnormal myocardial fiber morphology
|
|
GS191700: GO:0006753 nucleoside phosphate metabolic process
|
|
GS208012: GO:0044464 cell part
|
|
GS210212: GO:0005575 cellular_component
|
|
GS136595: rotarod performance 2 (Rrodp2, Published QTL Chr 2)
|
|
GS201239: GO:0046483 heterocycle metabolic process
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS135235: activity response to ethanol 2 (Actre2, Published QTL Chr 2)
|
|
GS184435: GO:0046483 heterocycle metabolic process
|
|
GS136914: vertebral morphology and mechanical traits 2 (Vmmt2, Published QTL Chr 2)
|
|
GS205825: GO:1901292 nucleoside phosphate catabolic process
|
|
GS136873: T cell ratio modifier QTL 3 (Trmq3, Published QTL Chr 2)
|
|
GS195113: GO:0071841 cellular component organization or biogenesis at cellular level
|
|
GS164261: MP:0002081 perinatal lethality
|
|
GS179580: GO:0036094 small molecule binding
|
|
GS135515: "body weight, QTL 5" (Bwq5, Published QTL Chr 2)
|
|
GS166719: MP:0010678 abnormal skin adnexa morphology
|
|
GS190492: GO:0009154 purine ribonucleotide catabolic process
|
|
GS135345: atherosclerotic lesion area 1 (Athla1, Published QTL Chr 2)
|
|
GS136360: Neuroadapted Sindbis viral RNA level 1 (Nsv1, Published QTL Chr 2)
|
|
GS166813: MP:0001951 abnormal breathing pattern
|
|
GS166711: MP:0002160 abnormal reproductive system morphology
|
|
GS177310: GO:1901360 organic cyclic compound metabolic process
|
|
GS196896: GO:0009205 purine ribonucleoside triphosphate metabolic process
|
|
GS136010: hemotopoietic response to early cytokines (Hrec, Published QTL Chr 2)
|
|
GS167020: MP:0003956 abnormal body size
|
|
GS165616: MP:0002127 abnormal cardiovascular system morphology
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS165789: MP:0005369 muscle phenotype
|
|
GS167367: MP:0002208 abnormal germ cell morphology
|
|
GS168477: MP:0002188 small heart
|
|
GS136055: IgA nephropathy QTL 1 (Ignpq1, Published QTL Chr 2)
|
|
GS182834: GO:0005623 cell
|
|
GS185640: GO:0035870 dITP diphosphatase activity
|
|
GS36418: Cerebellum Gene expression correlates of Open Field - Total rears 5-10 minutes in Males BXD
|
|
GS169953: MP:0001242 hyperkeratosis
|
|
GS199635: GO:0005622 intracellular
|
|
GS135407: body growth late QTL 2 (Bglq2, Published QTL Chr 2)
|
|
GS168012: MP:0010832 lethality during fetal growth through weaning
|
|
GS167116: MP:0004092 absent Z lines
|
|
GS203085: GO:0009146 purine nucleoside triphosphate catabolic process
|
|
GS84135: cocaine related behavior (Published QTL, Chr 2)
|
|
GS186758: GO:0034655 nucleobase-containing compound catabolic process
|
|
GS196943: GO:0008152 metabolic process
|
|
GS165244: MP:0010771 integument phenotype
|
|
GS169161: MP:0006362 abnormal male germ cell morphology
|
|
GS196941: GO:0008150 biological_process
|
|
GS199634: GO:0005623 cell
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS166117: MP:0002108 abnormal muscle morphology
|
|
GS36433: Cerebellum Gene expression correlates of Open Field - Total number of Rears in Males BXD
|
|
GS135704: diabetes mRNA cluster 1 (Dbmc1, Published QTL Chr 2)
|
|
GS198802: GO:0046041 ITP metabolic process
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS170577: MP:0005406 abnormal heart size
|
|
GS126276: pirinixic acid interacting genes (MeSH:C006253) in CTD
|
|
GS135287: alcohol response 2 (Alcrsp2, Published QTL Chr 2)
|
|
GS177169: GO:0051276 chromosome organization
|
|
GS168630: MP:0000377 abnormal hair follicle morphology
|
|
GS164339: MP:0002327 abnormal respiratory function
|
|
GS135858: femur breaking strength 1 (Fembrs1, Published QTL Chr 2)
|
|
GS136105: lymph node cytotoxic T lymphocyte percentage 1 (Lctlp1, Published QTL Chr 2)
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS195110: GO:0071842 cellular component organization at cellular level
|
|
GS136797: total body bone mineral density 2 (Tbbmd2, Published QTL Chr 2)
|
|
GS194504: GO:1901136 carbohydrate derivative catabolic process
|
|
GS135708: diabetes susceptibility QTL 5 (Dbsq5, Published QTL Chr 2)
|
|
GS135554: CD8 memory T cell subset 3 (Cd8mts3, Published QTL Chr 2)
|
|
GS198511: GO:0006163 purine nucleotide metabolic process
|
|
GS190496: GO:0009150 purine ribonucleotide metabolic process
|
|
GS196898: GO:0009203 ribonucleoside triphosphate catabolic process
|
|
GS207385: GO:0009154 purine ribonucleotide catabolic process
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS165260: MP:0001392 abnormal locomotor behavior
|
|
GS164482: MP:0001216 abnormal epidermal layer morphology
|
|
GS208636: GO:0006753 nucleoside phosphate metabolic process
|
|
GS129139: growth and fatness 4 (Gnf4 Published QTL Chr 2)
|
|
GS187770: GO:1901565 organonitrogen compound catabolic process
|
|
GS84133: activity response to ethanol (Published QTL, Chr 2)
|
|
GS129086: blood glucose level 1 (Bglu1 Published QTL Chr 2)
|
|
GS86789: Table S1: Cocaine Regulation of H3 Acetylation. [DRG]
provisional
|
|
GS127240: Acetaminophen interacting genes (MeSH:D000082) in CTD
|
|
GS164555: MP:0005329 abnormal myocardium layer morphology
|
|
GS135685: C. trachomatis resistance QTL 1 (Ctrq1, Published QTL Chr 2)
|
|
GS136950: weight gain in high growth mice 5 (Wg5, Published QTL Chr 2)
|
|
GS185991: GO:0016817 hydrolase activity, acting on acid anhydrides
|
|
GS165397: MP:0001265 decreased body size
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS185366: GO:0044248 cellular catabolic process
|
|
GS194041: GO:1901361 organic cyclic compound catabolic process
|
|
GS169095: MP:0004924 abnormal behavior
|
|
GS169836: MP:0005388 respiratory system phenotype
|
|
GS135373: body length 3 (Bdln3, Published QTL Chr 2)
|
|
GS201002: GO:0044270 cellular nitrogen compound catabolic process
|
|
GS135236: activity response to ethanol 3 (Actre3, Published QTL Chr 2)
|
|
GS187633: GO:0019693 ribose phosphate metabolic process
|
|
GS203082: GO:0009143 nucleoside triphosphate catabolic process
|
|
GS193491: GO:0072523 purine-containing compound catabolic process
|
|
GS34895: Whole Brain Gene expression correlates of Open Field - Total time in corners in Males BXD
|
|
GS186235: GO:0009141 nucleoside triphosphate metabolic process
|
|
GS184198: GO:0044270 cellular nitrogen compound catabolic process
|
|
GS192174: GO:0000166 nucleotide binding
|
|
GS135694: directional asymmetry QTL 18 (Daq18, Published QTL Chr 2)
|
|
GS164742: MP:0001732 postnatal growth retardation
|
|
GS191973: GO:0046700 heterocycle catabolic process
|
|
GS194505: GO:1901135 carbohydrate derivative metabolic process
|
|
GS209614: GO:0055086 nucleobase-containing small molecule metabolic process
|
|
GS127924: Cerebral cortex - Allen Mouse Brain Atlas
|
|
GS135795: ethanol induced low dose activation 3 (Elda3, Published QTL Chr 2)
|
|
GS208810: GO:0009259 ribonucleotide metabolic process
|
|
GS194087: GO:0003674 molecular_function
|
|
GS177356: GO:0003674 molecular_function
|
|
GS177309: GO:1901363 heterocyclic compound binding
|
|
GS34905: Whole Brain Gene expression correlates of Open Field - Total time in corners [Basal Behavior] in Males BXD
|
|
GS136588: renal disease susceptibility (Rends, Published QTL Chr 2)
|
|
GS180166: GO:0008152 metabolic process
|
|
GS203083: GO:0009144 purine nucleoside triphosphate metabolic process
|
|
GS203886: GO:1901265 nucleoside phosphate binding
|
|
GS136472: periosteal circumference and femur length 2 (Pcfm2, Published QTL Chr 2)
|
|
GS177382: GO:0097159 organic cyclic compound binding
|
|
GS136445: peripheral blood stem cell response to granulocyte colony stimulating factor 1 (Pbrgcsf1, Published QTL Chr 2)
|
|
GS136391: organ weight 1 (Org1, Published QTL Chr 2)
|
|
GS164724: MP:0001516 abnormal motor coordination/ balance
|
|
GS189844: GO:0009261 ribonucleotide catabolic process
|
|
GS168956: MP:0003491 abnormal voluntary movement
|
|
GS177766: GO:1901135 carbohydrate derivative metabolic process
|
|
GS186237: GO:0009143 nucleoside triphosphate catabolic process
|
|
GS195214: GO:0009987 cellular process
|
|
GS129156: multigenic obesity QTL 5 (Mobq5 Published QTL Chr 2)
|
|
GS193193: GO:0016462 pyrophosphatase activity
|
|
GS195112: GO:0071840 cellular component organization or biogenesis
|
|
GS169192: MP:0000280 thin ventricular wall
|
|
GS209029: GO:0047429 nucleoside-triphosphate diphosphatase activity
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS182009: GO:0046041 ITP metabolic process
|
|
GS203642: GO:0006725 cellular aromatic compound metabolic process
|
|
GS135855: femoral bone morphometry 4 (Fembm4, Published QTL Chr 2)
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS136915: vertebral morphology and mechanical traits 3 (Vmmt3, Published QTL Chr 2)
|
|
GS187023: GO:1901265 nucleoside phosphate binding
|
|
GS192296: GO:0006796 phosphate-containing compound metabolic process
|
|
GS198263: GO:0005488 binding
|
|
GS84136: ethanol induced locomotion (Published QTL, Chr 2)
|
|
GS194040: GO:1901360 organic cyclic compound metabolic process
|
|
GS86932: Table S3: CORTEX 17K MICROARRAY [DRG]
|
|
GS177765: GO:1901136 carbohydrate derivative catabolic process
|
|
GS195151: GO:0019637 organophosphate metabolic process
|
|
GS36423: Cerebellum Gene expression correlates of Open Field - Total number of Rears in Females & Males BXD
|
|
GS191870: GO:0009259 ribonucleotide metabolic process
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS208037: GO:0016787 hydrolase activity
|
|
GS209235: GO:0006793 phosphorus metabolic process
|
|
GS204496: GO:0019693 ribose phosphate metabolic process
|
|
GS165243: MP:0010770 preweaning lethality
|
|
GS135892: failure of ureteric bud invasion 1 (Fubi1, Published QTL Chr 2)
|
|
GS180120: GO:0009205 purine ribonucleoside triphosphate metabolic process
|
|
GS163553: MP:0003704 abnormal hair follicle development
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS135584: cholesterol absorption 1 (Chab1, Published QTL Chr 2)
|
|
GS36393: Cerebellum Gene expression correlates of Open Field - Total rears 15-20 minutes in Females & Males BXD
|
|
GS125069: Sodium Selenite interacting genes (MeSH:D018038) in CTD
|
|
GS180164: GO:0008150 biological_process
|
|
GS203080: GO:0009141 nucleoside triphosphate metabolic process
|
|
GS36580: Hippocampus Gene expression correlates of Novel Open Field Number of urinations in Males BXD
|
|
GS164004: MP:0011101 partial prenatal lethality
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS169829: MP:0005385 cardiovascular system phenotype
|
|
GS187769: GO:1901564 organonitrogen compound metabolic process
|
|
GS206780: GO:0009117 nucleotide metabolic process
|
|
GS136527: prion disease incubation time 1 (Prdt1, Published QTL Chr 2)
|
|
GS209232: GO:0006796 phosphate-containing compound metabolic process
|
|
GS36373: Cerebellum Gene expression correlates of Open Field - Total rears 0-5 minutes in Males BXD
|
|
GS164262: MP:0002080 prenatal lethality
|
|
GS136951: weight gain in high growth mice 6 (Wg6, Published QTL Chr 2)
|
|
GS167307: MP:0002925 abnormal cardiovascular development
|
|
GS190954: GO:0009056 catabolic process
|
|
GS209455: GO:0003824 catalytic activity
|
|
GS168520: MP:0004901 decreased male germ cell number
|
|
GS184218: GO:0071704 organic substance metabolic process
|
|
GS202822: GO:0016818 hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides
|
|
GS135951: HDL QTL 19 (Hdlq19, Published QTL Chr 2)
|
|
GS165764: MP:0004085 abnormal heartbeat
|
|
GS208954: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS135564: cytokine deficiency colitis susceptibility 3 (Cdcs3, Published QTL Chr 2)
|
|
GS181223: GO:0046434 organophosphate catabolic process
|
|
GS178461: GO:0009987 cellular process
|
|
GS34900: Whole Brain Gene expression correlates of Open Field - Total time in corners [Basal Behavior] in Females BXD
|
|
GS208912: GO:0046700 heterocycle catabolic process
|
|
GS192041: GO:0043169 cation binding
|
|
GS186240: GO:0009146 purine nucleoside triphosphate catabolic process
|
|
GS197054: GO:0006195 purine nucleotide catabolic process
|
|
GS129192: type 2 diabetes mellitus 2 in SMXA RI mice (T2dm2sa Published QTL Chr 2)
|
|
GS36408: Cerebellum Gene expression correlates of Open Field - Total rears 5-10 minutes in Females & Males BXD
|
|
GS193268: GO:0005575 cellular_component
|
|
GS194039: GO:1901363 heterocyclic compound binding
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS166162: MP:0011090 partial perinatal lethality
|
|
GS35810: Whole Brain Gene expression correlates of Cocaine CPP- Time (s) in drug-paired compartment a in Males BXD
|
|
GS163051: MP:0000267 abnormal heart development
|
|
GS136493: proteoglycan induced arthritis 2 (Pgia2, Published QTL Chr 2)
|
|
GS163852: MP:0001544 abnormal cardiovascular system physiology
|
|
GS202188: GO:0044248 cellular catabolic process
|
|
GS125959: Cisplatin interacting genes (MeSH:D002945) in CTD
|
|
GS86494: Table S1: Hippocampus 17 K microarray data. [DRG]
|
|
GS135604: circulating hormone level QTL 13 (Chlq13, Published QTL Chr 2)
|
|
GS192986: GO:0006996 organelle organization
|
|
GS192672: GO:0055086 nucleobase-containing small molecule metabolic process
|
|
GS169835: MP:0005389 reproductive system phenotype
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS180122: GO:0009203 ribonucleoside triphosphate catabolic process
|